文献速递血栓与止血

对乙酰氨基酚诱导肝衰竭小鼠中稳健的凝血激活与凝血病

Robust coagulation activation and coagulopathy in mice with experimental acetaminophen-induced liver failure.
PubMed 文献 · J Thromb Haemost · 2023-04-11

研究比较了对乙酰氨基酚(APAP)诱导的肝毒性/修复(300-450 mg/kg)与急性肝衰竭(ALF,600 mg/kg)小鼠的凝血激活与血浆凝血潜力。APAP诱导的ALF小鼠血浆凝血酶-抗凝血酶复合物升高、凝血酶原降低、纤维蛋白原显著减少,肝纤维蛋白(原)沉积独立于APAP剂量增加,血浆纤维蛋白(原)降解产物显著升高。早期药物抗凝可限制凝血激活并减少肝坏死,且ALF小鼠血浆在体外显示凝血酶原时间延长和组织因子启动的凝血形成受抑。

要点

  • APAP诱导的ALF小鼠血浆凝血酶-抗凝血酶复合物升高、凝血酶原降低、纤维蛋白原显著减少。
  • 肝纤维蛋白(原)沉积增加独立于APAP剂量,ALF小鼠血浆纤维蛋白(原)降解产物显著升高。
  • 早期药物抗凝可限制凝血激活并减少肝坏死。

核心结论

  • APAP诱导的ALF小鼠存在稳健的病理性凝血级联激活和体外凝血受抑,该实验设置可能填补ALF复杂凝血病机制研究模型的未满足需求。

研究设计与样本

  • 小鼠实验研究,比较APAP诱导的肝毒性/修复(300-450 mg/kg)与APAP诱导的ALF(600 mg/kg)设置下的在体凝血激活和体外血浆凝血潜力。

主要发现

  • 与较低APAP剂量相比,APAP诱导的ALF与血浆凝血酶-抗凝血酶复合物升高、血浆凝血酶原降低和血浆纤维蛋白原显著减少相关。
  • 肝纤维蛋白(原)沉积增加独立于APAP剂量,而实验性ALF小鼠血浆纤维蛋白(原)降解产物显著升高。
  • 在600 mg/kg APAP后2小时早期药物抗凝限制了凝血激活并减少了肝坏死。
  • APAP诱导的ALF小鼠中明显的凝血激活与体外可检测的血浆凝血病相关,即使恢复生理纤维蛋白原浓度后,凝血酶原时间延长和组织因子启动的凝血形成受抑仍明显。
  • 所有APAP剂量下血浆内源性凝血酶潜力均类似降低;在纤维蛋白原充足时,APAP诱导的ALF小鼠血浆比单纯肝毒性小鼠血浆需约10倍多的凝血酶才能凝固。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with acetaminophen (APAP)-induced acute liver failure (ALF) display both hyper- and hypocoagulable changes not necessarily recapitulated by standard hepatotoxic doses of APAP used in mice (eg, 300 mg/kg). OBJECTIVES: We sought to examine coagulation activation in vivo and plasma coagulation potential ex vivo in experimental settings of APAP-induced hepatotoxicity and repair (300-450 mg/kg) and APAP-induced ALF (600 mg/kg) in mice. RESULTS: APAP-induced ALF was associated with increased plasma thrombin-antithrombin complexes, decreased plasma prothrombin, and a dramatic reduction in plasma fibrinogen compared with lower APAP doses. Hepatic fibrin(ogen) deposits increased independent of APAP dose, whereas plasma fibrin(ogen) degradation products markedly increased in mice with experimental ALF. Early pharmacologic anticoagulation (+2 hours after 600 mg/kg APAP) limited coagulation activation and reduced hepatic necrosis. The marked coagulation activation evident in mice with APAP-induced ALF was associated with a coagulopathy detectable ex vivo in plasma. Specifically, prolongation of the prothrombin time and inhibition of tissue factor-initiated clot formation were evident even after restoration of physiological fibrinogen concentrations. Plasma endogenous thrombin potential was similarly reduced at all APAP doses. Interestingly, in the presence of ample fibrinogen, ∼10 times more thrombin was required to clot plasma from mice with APAP-induced ALF compared with plasma from mice with simple hepatotoxicity. CONCLUSION: The results indicate that robust pathologic coagulation cascade activation in vivo and suppressed coagulation ex vivo are evident in mice with APAP-induced ALF. This unique experimental setting may fill an unmet need as a model to uncover mechanistic aspects of the complex coagulopathy of ALF.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Groeneveld DJ, Poole LG, Bouck EG, et al. Robust coagulation activation and coagulopathy in mice with experimental acetaminophen-induced liver failure. J Thromb Haemost. 2023. PMID: 37054919. doi:10.1016/j.jtha.2023.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。